<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778425</url>
  </required_header>
  <id_info>
    <org_study_id>201602-QILU</org_study_id>
    <nct_id>NCT02778425</nct_id>
  </id_info>
  <brief_title>The Treatment of Hepatocirrhosis and Portal Hypertension</brief_title>
  <official_title>Partial Splenic Embolization Combined With Endoscopic Therapies and NSBB Decreases the Variceal Rebleeding Rate in Cirrhosis Patients With Hypersplenism: a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanjing Gao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinan Military General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compare the efficiency of partial splenic embolization +endoscopical therapy with&#xD;
      endoscopical therapy alone in gastroesophageal variceal haemorrhage accompanied with&#xD;
      splenomegaly or hypersplenism of hepatocirrhosis and portal hypertension treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic therapy is the mature treatment of gastroesophageal variceal haemorrhage and PSE&#xD;
      is an effective method for treatment of the hypersplenism and portal hypertension. Existing&#xD;
      researches show that endoscopic therapy + PSE is more effective than endoscopic therapy alone&#xD;
      in prevention of esophageal varices bleeding recurrence in the patients with liver cirrhosis.&#xD;
      However, there is few articles which proved long-term effectiveness of endoscopic therapy +&#xD;
      PSE, it needs further research on this issue. This study compares the efficiency of partial&#xD;
      splenic embolization +endoscopic therapy with endoscopic therapy alone in the treatment of&#xD;
      gastroesophageal variceal haemorrhage accompanied with splenomegaly or hypersplenism in the&#xD;
      patients with hepatocirrhosis and portal hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint was variceal rebleeding</measure>
    <time_frame>2 years</time_frame>
    <description>The rebleeding rate of the varices in the EP group will compared to that in the E group during the follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints were severe variceal recurrence and mortality during the 2-year follow-up</measure>
    <time_frame>2 years</time_frame>
    <description>The recurrence rate of the varices in the EP group will compared to that in the E group during the follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the peripheral blood cell counts including white blood cell, red blood cell, and platelate counts in both group during 2-years follow up.</measure>
    <time_frame>2 years</time_frame>
    <description>The physiological parameters including white blood cell (*10^9/L), red blood cell (*10^12/L) and platelte(*10^12/L) will compared between the two groups.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Secondary prevention-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic therapy+ beta blockers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary prevention-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic therapy+ PSE+beta blockers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary prevention-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beta blockers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary prevention-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary prevention-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic therapy+ PSE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute bleeding-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Somatostatin+endoscopic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute bleeding-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Somatostatin+endoscopic therapy+PSE</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic therapy+ beta blockers</intervention_name>
    <description>Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.</description>
    <arm_group_label>Secondary prevention-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic therapy+ PSE+beta blockers</intervention_name>
    <description>Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.</description>
    <arm_group_label>Secondary prevention-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>beta blockers</intervention_name>
    <description>A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.</description>
    <arm_group_label>Primary prevention-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic therapy</intervention_name>
    <description>Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).</description>
    <arm_group_label>Primary prevention-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic therapy+ PSE</intervention_name>
    <description>Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.</description>
    <arm_group_label>Primary prevention-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Somatostatin+Endoscopic therapy</intervention_name>
    <description>The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).</description>
    <arm_group_label>Acute bleeding-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Somatostatin+Endoscopic therapy+PSE</intervention_name>
    <description>The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.</description>
    <arm_group_label>Acute bleeding-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged between 18 and 75 years&#xD;
&#xD;
          -  Patients who had recovered from an episode of VH or patients who had survived from&#xD;
             acute VH and there was no bleeding for consecutive 5 days&#xD;
&#xD;
          -  Patients with a diagnosis of liver cirrhosis and portal hypertension on clinical&#xD;
             examination, laboratory test, and imaging or histological examination&#xD;
&#xD;
          -  Patients with hypersplenism and thrombocytopenia (platelets &lt; 100,000/µL).&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Previous therapy (splenectomy, PSE, EVL, tissue adhesive injection, or usage of (NSBB)&#xD;
             to prevent rebleeding&#xD;
&#xD;
          -  Bleeding from isolated gastric or ectopic varices&#xD;
&#xD;
          -  Hepatocellular carcinoma or other malignant tumors&#xD;
&#xD;
          -  Contraindications for the use of NSBBs, hepatic failure, and Child-Pugh class C with&#xD;
             large amount ascites, or grade 3-5 hepatic encephalopathy, or prothrombin activity ≤&#xD;
             40%&#xD;
&#xD;
          -  Hepatic failure&#xD;
&#xD;
          -  Contraindications for PSE&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  Inability to sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanjing Gao Yanjing Gao, PhD.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital,Shandong Universty</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology,Qilu Hospital,Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 8, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Yanjing Gao</investigator_full_name>
    <investigator_title>Vice presidengt of Department of Gastroenterology of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>Partial splenic embolization</keyword>
  <keyword>Hypersplenism</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Gastroesophageal varices</keyword>
  <keyword>Secondary prophylaxis</keyword>
  <keyword>Endoscopic variceal ligation</keyword>
  <keyword>Non-selective beta-blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All the individual participant data (IPD) available to other researchers.</ipd_description>
    <ipd_time_frame>2021.1</ipd_time_frame>
    <ipd_access_criteria>Open Access</ipd_access_criteria>
    <ipd_url>https://doi.org/10.1007/s12072-021-10155-0</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

